首页|缺血性卒中血管内治疗后无效再通标志物的研究进展

缺血性卒中血管内治疗后无效再通标志物的研究进展

扫码查看
急性缺血性卒中具有高致死率和致残率,严重危害人类的健康。目前,血管内治疗已经成为急性缺血性卒中主要的治疗方式之一。然而,仍有部分患者血管内治疗后血管成功再通(改良脑梗死溶栓分级2b级或3级),但术后90 d神经功能预后不良(改良Rankin量表评分>2分),这种现象被称为无效再通。该综述拟对无效再通的机制及其基线特征、血液、影像学等标志物进行总结,以期帮助临床医师早发现、早识别可能发生无效再通患者,为预防和治疗无效再通提供思路。
Research progress on biomarkers of futile recanalization after endovascular thrombectomy in ischemic stroke
Acute ischemic stroke has a high mortality and disability rate,posing a serious threat to human health.Endovascular treatment is now a first-line approach for acute ischemic stroke.However,some patients achieving successful revascularization(modified thrombolysis in cerebral infarction grade 2b or 3)still have poor neurological outcomes(midified Rankin scale score>2)90 days after the procedure,a phenomenon known as futile recanalization.This review aims to summarize the mechanisms and baseline characteristics,blood markers,and imaging markers of futile recanalization,helping clinicians identify and detect at-risk patients early.This will provide insights for the prevention and management of futile recanalization.

Acute ischemic strokeEndovascular thrombectomyFutile recanalizationBiomarkerReview

吕猛、徐率立、戴缤

展开 >

100038 首都医科大学附属北京世纪坛医院神经外科

北京脑重大疾病研究院

急性缺血性卒中 血管内治疗 无效再通 标志物 综述

2024

中国脑血管病杂志
中国医师协会 首都医科大学宣武医院

中国脑血管病杂志

CSTPCD北大核心
影响因子:1.076
ISSN:1672-5921
年,卷(期):2024.21(12)